

## Gilead and Kite Research Scholars Program in Hematologic Malignancies

**Advancing Science Together** 

https://researchscholars.gilead.com/en/intl\_hematologic\_malignancies\_portal CH-UNB-0545

GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies. Kite and the Kite logo are registered trademarks of Kite, a Gilead company. © 2021 Gilead Sciences, Inc. All rights reserved.

# **Table of Contents**

Gilead's Research Scholars Program	3
Hematologic Malignancies Program Overview	
Program Timeline	
Application Information	4
Eligibility	
Requirements	
Criteria for Selection	
Budget Guidelines	5
Scientific Review Committee	6
Chair	
Committee	
Contact Information	7

2



### **Gilead's Research Scholars Program**

Gilead's Research Scholars Program supports innovative research from emerging investigators around the world to advance scientific knowledge in areas of unmet medical needs and improve the lives of patients everywhere.

Since 2008, Gilead's Research Scholars Program has invested more than \$31 million USD into meaningful research conducted by more than 235 scholars.

Gilead's Research Scholars Program is committed to building a more diverse and inclusive scientific community. Award selections are made without discrimination based on race, ethnicity, religion, national origin, gender, age, sexual orientation, physical or mental disability, genetic information or characteristic, gender identity and expression.

Visit www.Gilead.com/RSP to learn more.

### Hematologic Malignancies Program Overview

The program is designed to support innovative translational research projects in hematologic malignancies that can be based around either a clinical trial or laboratory investigation.

Each award is funded up to \$130,000 USD over two years, paid as annual installments of \$65,000 USD per year directly to the scholar's institution. Funding for the second year is contingent upon submission of a progress report and approval by the Scientific Review Committee Chair.

### **Program Timeline**

From application submission to award disbursement, the timeline for the Hematologic Malignancies Program is as follows:

Application deadline: 21 March 2022

Applicant notification: 1 June 2022



"The Gilead Research Scholars program allowed me to fund critical research at an early stage of my independent career, which I could not have done without the award."

– Dr. Daniel Hodson



### **Application Information**

Applications will be reviewed and selected by an independent <u>Scientific Review Committee</u> comprised of internationally recognized experts in basic and clinical research in the field of hematology/oncology.

### **Eligibility**

The Research Scholars Program in Hematologic Malignancies is open to emerging investigators from the following countries\*:

#### Europe, Asia, Australasia and South America

## Applicants must meet the following requirements:

- Hold an MD or PhD (equivalent degree) at the time of award.
- Early to Mid-career scientists with a strong research track record who hold a position at a recognized research institution in one of the eligible countries at the time of application (see above for list of countries) and whose tenure of that position encompasses the projected period of the award from the Gilead and Kite scholarship program
- This program is designed for non-faculty members who are within 3-5 years of obtaining a faculty appointment. MD or PhD qualifications would have to have been obtained within the last 8 years. Exceptions can apply.
- Have a strong career interest in hematology/ oncology
- Have a research mentor with extensive experience in the field of hematology/oncology
- Be able to devote approximately 50% of their professional time to research for the next two years
- Be able to complete the proposed research within the two-year award period.

\*An applicant must be a citizen or permanent resident of one of the eligible countries or subject to the requirements noted below with regards to temporary visa/work permit. This visa must be valid for the duration of the award period or the applicant must be able to demonstrate that they are eligible for an extension, renewal or other status that will enable the applicant to undertake the research for the entirety of the two-year award.

### **Criteria for Selection**

In their evaluation, the Committee will consider the following criteria:

- Evaluation of the applicant
- Evaluation of the Mentor Support and Mentoring Plan
- Evaluation of the proposal

Awards granted under the program may not be duplicative of funding from institutional or hospital, other governmental, non-governmental or industry sources. Applicants seeking an award for research projects that are currently receiving or may receive partial funding from other sources are required to submit appropriate evidence, as outlined in the current and pending funding form.

Proposals utilizing Gilead product(s) are not eligible for funding through the Research Scholars Program. Proposals involving Gilead product(s) should be submitted for review under the Investigator-Sponsored Research Grant Program through the **ISR online portal.** 

Applications must be completed online and submitted electronically with the required supplementary materials.

Visit the Research Scholars Program application portal for detailed information about eligibility, application requirements and supplementary materials, research proposal guidelines, and criteria for selection.



### **Budget Guidelines**

### **Indirect Costs**

In an effort to maximize the research benefit of the award, the program encourages that every effort be made to minimize the utilization of the award to cover indirect costs. Indirect costs may not exceed 10% of the award value, and are included as part of the budget, not as an addition to the value of the award (subject to local variances to be approved by Gilead Sciences). Indirect costs are defined as overhead costs paid directly to the institution, for example maintenance of labs/space and departmental/admin costs.

#### **S**alaries

The applicant may allocate up to \$50,000 USD per year in salary and fringe benefits support for the applicant and/or a technician. Salaries and fringe benefits for mentors, post-doctoral fellows, or students may not be included.

### **Supplies**

Supplies such as disposables, chemicals, reagent kits, animals, etc., may be included. Equipment purchases with a single item value of greater than \$2,500 USD may not be included.

#### **Travel**

Up to \$1,500 USD per year for applicant's travel to a scientific meeting for presentation of project data may be included.

Visit <u>https://researchscholars.gilead.com/en/</u> <u>intl\_hematologic\_malignancies\_portal</u> for complete program information, including comprehensive details on eligibility, evaluation criteria, research proposal guidelines, application materials, budget guidelines and funding



"The Gilead Research Scholars Program award provided additional support and funding to really make my research more innovative."

– Dr. Kristine Mace Erlandson



### **Scientific Review Committee**

Applications will be reviewed by the Committee, comprised of internationally recognized experts in basic and clinical research in the field of hematology/oncology:

### Chair



**Pier Luigi Zinzani, MD, PhD** Professor of Hematology Institute of Hematology "Seràgnoli" University of Bologna Bologna, Italy

### Committee



Paolo Ghia, MD, PhD Professor, Medical Oncology Internal Medicine Università Vita-Salute San Raffaele Director, Strategic Research Program on CLL Division of Experimental Oncology Istituto Scientifico San Raffaele Milan, Italy



**Christiane Pott, MD** Professor. Dr. med. University Hospital Schleswig-Holstein Medical Department II Hematology and Oncology Germany



Marie José Kersten, MD, PhD Dean of the Hematology Fellowship Amsterdam UMC, loc. AMC Amsterdam, The Netherlands



Anna Sureda, MD, PhD Associate Professor Head of Department Universitat de Barcelona, Spain Hematology Department Institut Catalá d'Oncologia-Hospitalet Barcelona, Spain



Won Seog Kim, MD, PhD Professor, Division of Hematology/Oncology Samsung Medical Center Sungkyunkwan University School of Medicine South Korea





## **Contact Information**

For general inquiries about the Research Scholars Program in Hematologic Malignancies please call or email:

#### **Gilead's Research Scholars Program Coordinator**

Telephone: +44 7929 728979 Email: euresearchscholarsprogrammes@bcdme.com



https://researchscholars.gilead.com/en/intl\_hematologic\_malignancies\_portal